Senseonics Holdings, Inc. is a medical technology company focused on the development and commercialization of long-term, implantable continuous glucose monitoring (CGM) systems, including Eversense E3 (6-month) and Eversense 365 (12-month) systems. The Eversense 365 CGM system received FDA approval in September 2024, with commercialization commencing in Q4 2024. Full commercial responsibility for Eversense 365 in the United States was taken over from Ascensia on January 1, 2026. CE Mark approval for Eversense 365 was obtained in January 2026, with an expected launch in European Territories by the second half of 2026. Total net revenue increased to $35.3 million for the year ended December 31, 2025, up from $22.5 million in 2024. Gross profit rose significantly to $15.8 million in 2025, compared to $0.5 million in 2024, with gross margin improving to 44.7% from 2.4%. Net loss decreased to $(69.1) million in 2025, an improvement from $(78.6) million in 2024. An accumulated deficit of $1.0 billion was reported as of December 31, 2025. Cash, cash equivalents, and marketable securities totaled $94.0 million as of December 31, 2025. Management has expressed substantial doubt about the ability to continue as a going concern for the next twelve months due to liquidity and potential debt covenant issues. Developing next-generation products, including the Gemini system (2-in-1 CGM/flash, self-powered) targeted for Q4 2027, and the Freedom system (Bluetooth in sensor, no on-body component) targeted for Q4 2028. Acquired the sensor insertion network assets of NPG in October 2024, establishing the Eon Care Network to expand patient access. A new direct-to-consumer marketing campaign, 'One Year. One CGM.', was launched in October 2024, leading to increased leads, patient shipments, new prescribers, and prescriptions.